Bayer to invest $2.2 billion in new manufacturing site in Ohio
A new manufacturing site would add future production capacity and shift supply toward Ohio.
Source →The trace
How it reaches your house.
Starting from Bayer (Radiology), we walked the supply graph hop by hop to the goods you buy and the companies you own. Each step is the engine’s reasoning, scored for confidence and cited where a source backs it.
First impact
Bayer AG →supply upBayer new pharmaceutical manufacturing site in New Albany, Ohio
Bayer’s announced $2.2 billion project is explicitly a new pharmaceutical manufacturing site in Ohio, so the facility itself gains future production capacity and supply output.
“Bayer and JobsOhio today to announce Bayer’s plans to invest $2.2 billion in a new pharmaceutical manufacturing site in New Albany, Ohio.”
95% confidenceCited →Merck KGaA (MilliporeSigma in US) →Stands to benefitBayer’s $2.2B Ohio manufacturing site adds future drug-production capacity, and Merck has a disclosed collaboration/revenue tie to Bayer, so Bayer is the beneficiary here even though the effect is delayed until the plant comes online.
62% confidenceBayer (Radiology) →supply upIodinated Contrast Media (CT/MRI/Angiography)
Bayer is adding manufacturing capacity, and this edge shows it supplies roughly 25% of this contrast-media market with only moderate substitutability, so the expansion should lift availability.
56% confidenceHop 2
Iodinated Contrast Media (CT/MRI/Angiography) →supply upDiagnostic tests and lab supplies
More Ohio production capacity should raise availability of iodinated contrast media, and this is a critical 0.7-dependency input for diagnostic tests and lab supplies.
84% confidence
Where it lands
What you buy, and what you own.
Goods you buy
Diagnostic tests and lab supplies
Companies you may own
Bayer AG
Tap a company to see what it told the SEC could break it.
In the MyPRIA app, this is checked against your own holdings.